A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human SkinCitation formats

  • External authors:
  • Philip Foden
  • Mohsin Mazhari
  • S. Al-Habba
  • Mohamed Baguneid
  • Douglas McGeorge

Standard

A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin. / Ud-Din, Sara; Foden, Philip; Mazhari, Mohsin; Al-Habba, S.; Baguneid, Mohamed; Bulfone-Paus, Silvia; McGeorge, Douglas; Bayat, Ardeshir.

In: Journal of Investigative Dermatology, Vol. 139, No. 8, 08.2019, p. 1680-1690.e16.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Ud-Din, Sara ; Foden, Philip ; Mazhari, Mohsin ; Al-Habba, S. ; Baguneid, Mohamed ; Bulfone-Paus, Silvia ; McGeorge, Douglas ; Bayat, Ardeshir. / A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin. In: Journal of Investigative Dermatology. 2019 ; Vol. 139, No. 8. pp. 1680-1690.e16.

Bibtex

@article{1cb6454d15af4813bfb1d15cf0e40e5f,
title = "A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin",
abstract = "Background: Epigallocatechin-3-gallate (EGCG), a polyphenol, influences cutaneous wound healing because of its antiangiogenic, anti-inflammatory, and antioxidant properties. We previously showed the role of EGCG in scarring in ex vivo human scar models. Here, we evaluate direct application of topical EGCG compared with zonal priming, a unique concept in the immediate treatment of the zone of injury at the time of wounding before scar formation. Trial design: Double-blind randomized controlled trial. Methods: We assessed EGCG application compared with placebo over 1–6 weeks in scars created in 62 human volunteers using quantitative noninvasive devices, immunohistochemical analysis, mRNA sequencing, and quantitative real-time reverse transcriptase–PCR of tissue biopsy samples. Results: EGCG reduced mast cells at weeks 1–3, as evidenced by gene and protein analyses (P ≤ 0.01). M2 macrophages were increased with EGCG compared with placebo. EGCG application by zonal priming significantly down-regulated VEGFA and CD31 at week 1 and at 1–2 weeks after direct application (P ≤ 0.01). Direct EGCG application also reduced scar thickness at weeks 1–3 (P = 0.001) and increased scar elasticity at week 4 (P = 0.01). Increased hydration was evident both noninvasively and by increased hyaluronic acid levels (P < 0.01) at week 3. Conclusions: We show the beneficial role of both zonal priming and direct EGCG application in scar therapy with positive effects on scar thickness, erythema, hydration, and elasticity. Trial register: International standard randomized controlled trial, registration number ISRCTN 18643079; July 16, 2018.",
author = "Sara Ud-Din and Philip Foden and Mohsin Mazhari and S. Al-Habba and Mohamed Baguneid and Silvia Bulfone-Paus and Douglas McGeorge and Ardeshir Bayat",
year = "2019",
month = aug,
doi = "10.1016/j.jid.2019.01.030",
language = "English",
volume = "139",
pages = "1680--1690.e16",
journal = "The Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Springer Nature",
number = "8",

}

RIS

TY - JOUR

T1 - A Double-Blind, Randomized Trial Shows the Role of Zonal Priming and Direct Topical Application of Epigallocatechin-3-Gallate in the Modulation of Cutaneous Scarring in Human Skin

AU - Ud-Din, Sara

AU - Foden, Philip

AU - Mazhari, Mohsin

AU - Al-Habba, S.

AU - Baguneid, Mohamed

AU - Bulfone-Paus, Silvia

AU - McGeorge, Douglas

AU - Bayat, Ardeshir

PY - 2019/8

Y1 - 2019/8

N2 - Background: Epigallocatechin-3-gallate (EGCG), a polyphenol, influences cutaneous wound healing because of its antiangiogenic, anti-inflammatory, and antioxidant properties. We previously showed the role of EGCG in scarring in ex vivo human scar models. Here, we evaluate direct application of topical EGCG compared with zonal priming, a unique concept in the immediate treatment of the zone of injury at the time of wounding before scar formation. Trial design: Double-blind randomized controlled trial. Methods: We assessed EGCG application compared with placebo over 1–6 weeks in scars created in 62 human volunteers using quantitative noninvasive devices, immunohistochemical analysis, mRNA sequencing, and quantitative real-time reverse transcriptase–PCR of tissue biopsy samples. Results: EGCG reduced mast cells at weeks 1–3, as evidenced by gene and protein analyses (P ≤ 0.01). M2 macrophages were increased with EGCG compared with placebo. EGCG application by zonal priming significantly down-regulated VEGFA and CD31 at week 1 and at 1–2 weeks after direct application (P ≤ 0.01). Direct EGCG application also reduced scar thickness at weeks 1–3 (P = 0.001) and increased scar elasticity at week 4 (P = 0.01). Increased hydration was evident both noninvasively and by increased hyaluronic acid levels (P < 0.01) at week 3. Conclusions: We show the beneficial role of both zonal priming and direct EGCG application in scar therapy with positive effects on scar thickness, erythema, hydration, and elasticity. Trial register: International standard randomized controlled trial, registration number ISRCTN 18643079; July 16, 2018.

AB - Background: Epigallocatechin-3-gallate (EGCG), a polyphenol, influences cutaneous wound healing because of its antiangiogenic, anti-inflammatory, and antioxidant properties. We previously showed the role of EGCG in scarring in ex vivo human scar models. Here, we evaluate direct application of topical EGCG compared with zonal priming, a unique concept in the immediate treatment of the zone of injury at the time of wounding before scar formation. Trial design: Double-blind randomized controlled trial. Methods: We assessed EGCG application compared with placebo over 1–6 weeks in scars created in 62 human volunteers using quantitative noninvasive devices, immunohistochemical analysis, mRNA sequencing, and quantitative real-time reverse transcriptase–PCR of tissue biopsy samples. Results: EGCG reduced mast cells at weeks 1–3, as evidenced by gene and protein analyses (P ≤ 0.01). M2 macrophages were increased with EGCG compared with placebo. EGCG application by zonal priming significantly down-regulated VEGFA and CD31 at week 1 and at 1–2 weeks after direct application (P ≤ 0.01). Direct EGCG application also reduced scar thickness at weeks 1–3 (P = 0.001) and increased scar elasticity at week 4 (P = 0.01). Increased hydration was evident both noninvasively and by increased hyaluronic acid levels (P < 0.01) at week 3. Conclusions: We show the beneficial role of both zonal priming and direct EGCG application in scar therapy with positive effects on scar thickness, erythema, hydration, and elasticity. Trial register: International standard randomized controlled trial, registration number ISRCTN 18643079; July 16, 2018.

UR - http://www.scopus.com/inward/record.url?scp=85066938928&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2019.01.030

DO - 10.1016/j.jid.2019.01.030

M3 - Article

C2 - 30822414

AN - SCOPUS:85066938928

VL - 139

SP - 1680-1690.e16

JO - The Journal of Investigative Dermatology

JF - The Journal of Investigative Dermatology

SN - 0022-202X

IS - 8

ER -